ストックスクリーナーアプリを入手
0.0195
74.11%
0.0083
アフターアワーズ：
.02
0.0005
+2.56%
前日終値:
$0.0112
開ける：
$0.0115
24時間の取引高:
52,841
Relative Volume:
1.80
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+77.27%
1か月 パフォーマンス:
+116.67%
6か月 パフォーマンス:
-51.13%
1年 パフォーマンス:
-59.63%
1日の値動き範囲:
$0.0091
$0.0196
1週間の範囲:
$0.0088
$0.0196
52週間の値動き範囲:
$0.005
$0.1001
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
NLSPW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0195 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ag (NLSPW) 最新ニュース
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia
NLS Pharmaceutics sets terms for $1M private placement - Investing.com
NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa
NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com
NLS Pharmaceutics reveals promising preclinical data - Investing.com
NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria
NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
Nls Pharmaceutics Ag (NLSPW) 財務データ
Nls Pharmaceutics Ag (NLSPW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.50%
1.47%
大文字化:
|
ボリューム (24 時間):